Advancing in-vitro drug precipitation testing: new process monitoring tools and a kinetic nucleation and growth model

被引:41
作者
Arnold, Yvonne E. [1 ,2 ]
Imanidis, Georgios [1 ,2 ]
Kuentz, Martin T. [1 ]
机构
[1] Univ Appl Sci NW Switzerland, Inst Pharma Technol, CH-4132 Muttenz, Switzerland
[2] Univ Basel, Div Pharmaceut Technol, Basel, Switzerland
关键词
drug precipitation; dynamic image analysis; kinetic nucleation and growth model; Raman spectroscopy; ORAL ABSORPTION; GASTRIC PH; WEAK BASES; DISSOLUTION;
D O I
10.1111/j.2042-7158.2010.01228.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives Poorly soluble weak bases often precipitate during intestinal passage, potentially leading to incomplete drug absorption. The underlying in-vivo and in-vitro drug precipitation mechanisms are not well understood. Thus, new analytical tools and a kinetic nucleation and growth model were introduced to in-vitro drug precipitation testing in biorelevant media. Methods A drug precipitation test was used to simulate the transfer from the stomach to the intestine. Changes in the acceptor vessel were monitored using online dynamic image analysis and inline Raman spectroscopy. The concentration profiles of the model drug dipyridamole were analysed by high-performance liquid chromatography and the resulting data were fitted with a set of differential equations. Key findings The dynamic image analysis revealed a complex structure of the precipitated dipyridamole particles, which were described as star-like crystals or aggregates of elongated primary particles. Raman spectroscopy allowed the precipitation over time to be monitored. Using the kinetic nucleation and growth model to describe this process demonstrated perfect agreement with the experimental data. Conclusions The analytical methods and the kinetic model provided new insights into biorelevant drug precipitation and could in the future support formulation development.
引用
收藏
页码:333 / 341
页数:9
相关论文
共 22 条
[1]   Formulation of solid dosage forms to overcome gastric pH interaction of the factor Xa inhibitor, BMS-561389 [J].
Badawy, SIF ;
Gray, DB ;
Zhao, F ;
Sun, DX ;
Schuster, AE ;
Hussain, MA .
PHARMACEUTICAL RESEARCH, 2006, 23 (05) :989-996
[2]   INCREASED GASTRIC PH AND THE BIOAVAILABILITY OF FLUCONAZOLE AND KETOCONAZOLE [J].
BLUM, RA ;
DANDREA, DT ;
FLORENTINO, BM ;
WILTON, JH ;
HILLIGOSS, DM ;
GARDNER, MJ ;
HENRY, EB ;
GOLDSTEIN, H ;
SCHENTAG, JJ .
ANNALS OF INTERNAL MEDICINE, 1991, 114 (09) :755-757
[3]   Supersaturating Drug Delivery Systems: The Answer to Solubility-Limited Oral Bioavailability? [J].
Brouwers, Joachim ;
Brewster, Marcus E. ;
Augustijns, Patrick .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2009, 98 (08) :2549-2572
[4]   Physicochemical and physiological mechanisms for the effects of food on drug absorption: The role of lipids and pH [J].
Charman, WN ;
Porter, CJH ;
Mithani, S ;
Dressman, JB .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1997, 86 (03) :269-282
[5]   Using a novel multicompartment dissolution system to predict the effect of gastric pH on the oral absorption of weak bases with poor intrinsic solubility [J].
Gu, CH ;
Rao, D ;
Gandhi, RB ;
Hilden, J ;
Raghavan, K .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2005, 94 (01) :199-208
[6]   Dissolution media simulating conditions in the proximal human gastrointestinal tract: An update [J].
Jantratid, Ekarat ;
Janssen, Niels ;
Reppas, Christos ;
Dressman, Jennifer B. .
PHARMACEUTICAL RESEARCH, 2008, 25 (07) :1663-1676
[7]  
Kirwan D. J., 2002, HDB IND CRYSTALLIZAT
[8]   Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine [J].
Kostewicz, ES ;
Wunderlich, M ;
Brauns, U ;
Becker, R ;
Bock, T ;
Dressman, JB .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2004, 56 (01) :43-51
[9]   THEORY, PRODUCTION AND MECHANISM OF FORMATION OF MONODISPERSED HYDROSOLS [J].
LAMER, VK ;
DINEGAR, RH .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1950, 72 (11) :4847-4854
[10]  
LETHO P, 2009, J PHARM SCI, V98, P985